omniture
logo
Search
BIOSYNGEN PTE. LTD.
Media Room

Photo News

rss
Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

2024-02-01 17:41 1709
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

2023-10-26 18:18 1876
Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

2023-09-18 17:53 1457
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

2023-09-11 14:53 1127
Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

2023-07-12 10:32 2544
Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

2023-06-29 17:14 2769
Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

2023-06-06 12:58 2487
Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

2023-04-18 19:03 3099
Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

2023-04-11 18:09 2144
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

2023-03-29 22:53 2766
Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

2023-02-17 23:13 7344
IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

2022-12-15 13:08 3672
Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

2022-09-28 17:34 4204
Embracing Win-win Cooperation - ASEAN Consul Generals, officials and representatives of chambers of commerce in Guangzhou visited Biosyngen

Embracing Win-win Cooperation - ASEAN Consul Generals, officials and representatives of chambers of commerce in Guangzhou visited Biosyngen

2022-05-28 09:00 6643
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City

French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City

2022-01-15 08:00 4769
Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China

Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China

2021-12-29 10:00 4397
Singapore-based Biosyngen receives 500 million yuan in investment

Singapore-based Biosyngen receives 500 million yuan in investment

2021-10-21 09:30 4083